Doctor Janice Chew-Harris

Doctor Janice Chew-Harris

University of Otago Christchurch, Christchurch (New Zealand)

Dr Janice Chew-Harris received her PhD degree from University of Otago in Christchurch, New Zealand at the end of 2016. Her research is focused on measurements and detection of novel plasma and urinary biomarkers. Her current research aims to assess the performances of biomarkers and their prognostic abilities in predicting risk, earlier detection and in guiding therapy, in both acute and progressive forms of cardiac and renal diseases. She is also interested in studies relating to mechanisms and modulation of cardiorenal syndromes. She has previously worked as a medical laboratory scientist (Clinical Biochemistry) and is trained in many advanced laboratory methods.

Presentations

Comparative performances of soluble urokinase plasminogen activator receptor and Mid-regional proADM to predict composite death and new heart failure rehospitalisation in acutely breathless patients

Event: ESC Congress 2022

Topic: Biomarkers

Session: Acute heart failure - Biomarkers

Access

Prognostic performance of soluble urokinase plasminogen activator receptor for 1-year mortality in Asian and Western patients with acute breathlessness

Event: ESC Congress 2020

Topic: Biomarkers

Session: Novel Biomarkers for Early Risk Stratification in Acute Heart Failure

Access

Soluble urokinase plasminogen activator receptor (suPAR) predicts 2-year cardiovascular events in patients after acute chest pain

Event: ESC Congress 2020

Topic: Biomarkers

Session: Acute Coronary Syndromes ePosters

Access

Soluble urokinase plasminogen activator receptor (suPAR) can predict long-term mortality in patients with acute chest pain

Event: ESC Congress 2020

Topic: Biomarkers

Session: Acute Coronary Syndromes ePosters

Access

Soluble urokinase plasminogen activator receptor (suPAR) predicts 1 year mortality in patients with acute breathlessness

Event: ESC Congress 2019

Topic: Biomarkers

Session: Acute heart failure 1

Access

Soluble urokinase plasminogen activator receptor (suPAR) predicts 2-year cardiovascular events in patients after acute chest pain

Event: ESC Asia with APSC & AFC 2020

Topic: Biomarkers

Session: Abstract Programme

Access

Soluble urokinase plasminogen activator receptor (suPAR) can predict long-term mortality in patients with acute chest pain

Event: ESC Asia with APSC & AFC 2020

Topic: Biomarkers

Session: Abstract Programme

Access

Prognostic performance of soluble urokinase plasminogen activator receptor for 1-year mortality in Asian and Western patients with acute breathlessness

Event: ESC Asia with APSC & AFC 2020

Topic: Biomarkers

Session: Abstract Programme

Access

Doctor Janice Chew-Harris

Biography

Contributor content

Comparative performances of soluble urokinase plasminogen activator receptor and Mid-regional proADM to predict composite death and new heart failure rehospitalisation in acutely breathless patients

Prognostic performance of soluble urokinase plasminogen activator receptor for 1-year mortality in Asian and Western patients with acute breathlessness

Soluble urokinase plasminogen activator receptor (suPAR) predicts 2-year cardiovascular events in patients after acute chest pain

Soluble urokinase plasminogen activator receptor (suPAR) can predict long-term mortality in patients with acute chest pain

Soluble urokinase plasminogen activator receptor (suPAR) predicts 1 year mortality in patients with acute breathlessness

Soluble urokinase plasminogen activator receptor (suPAR) predicts 2-year cardiovascular events in patients after acute chest pain

Soluble urokinase plasminogen activator receptor (suPAR) can predict long-term mortality in patients with acute chest pain

Prognostic performance of soluble urokinase plasminogen activator receptor for 1-year mortality in Asian and Western patients with acute breathlessness

ESC 365 is supported by